National Guideline Clearinghouse | Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262).

full-text ►

National Guideline Clearinghouse | Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262).



National Institute for Health and Care Excellence (NICE)

Guideline Title

Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262).

Bibliographic Source(s)

National Institute for Health and Care Excellence (NICE). Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262). London (UK): National Institute for Health and Care Excellence (NICE); 2015 Feb. 70 p. (Technology appraisal guidance; no. 329).

Guideline Status

This is the current release of the guideline.

This guideline updates a previous version: National Institute for Health and Clinical Excellence (NICE). Infliximab for subacute manifestations of ulcerative colitis. London (UK): National Institute for Health and Clinical Excellence (NICE); 2008 Apr. 21 p. (Technology appraisal guidance; no. 140).

This guideline meets NGC's 2013 (revised) inclusion criteria.